Drilldown: Medicines
Medicines > routes:
oral 
& onset :
30–60 min or
Pain and migraine prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks
& onset :
30–60 min or
Pain and migraine prophylaxis effect 1-4 weeks; antidepressant effect 4-6 weeks Use the filters below to narrow your results.
brand:
classes:
CNS stimulant (1) ·
NDRI (1) ·
PDE5 Inhibitor (1) ·
Psychostimulant (1) ·
secondary amine)]] (1) ·
[[:Category:Antidepressants|Antidepressant]] (1) ·
[[:Category:Migraine prophylactics|Migraine prophylactic]] (1) ·
[[:Category:Neuropathic pain medicines|Neuropathic pain medicine]] (1) ·
[[:Category:Tricyclic antidepressants|Tricyclic antidepressant (TCA (1)
mechanism:
Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) ·
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) ·
'"`UNIQ--vote-00000019-QINU`"' Therapeutic plasma-level monitoring is standard practice for TCAs given the narrow therapeutic index and the established plasma-level-efficacy correlation. CYP2D6 substrate; CPIC PGx guidance applies for dose individualization'"`UNIQ--ref-0000001A-QINU`"'. (1)
uses:
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1) ·
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) ·
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1)
starting dose:
preparations:
fda max:
routes: (Click arrow to add another value)
onset: (Click arrow to add another value)
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 3 results in range #1 to #3.